Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.
| Autor: | Sayuk GS; Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA.; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; Gastroenterology Section, John Cochran Veterans Affairs Medical Center, St. Louis, Missouri, USA., Waldman SA; Departments of Pharmacology and Experimental Therapeutics and Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Brenner DM; Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The American journal of gastroenterology [Am J Gastroenterol] 2022 Apr 01; Vol. 117 (4S), pp. S6-S13. |
| DOI: | 10.14309/ajg.0000000000001687 |
| Abstrakt: | Multiple therapeutic agents are currently available for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. A better understanding of the mechanism of action of each treatment provides important insights into expected responses and is key to optimizing treatment outcomes. Some constipation treatments, such as stimulant laxatives, may increase bowel movement frequency but are ineffective at relieving, and may even exacerbate, abdominal symptoms. On the contrary, prescription treatments, such as the guanylyl cyclase-C agonists, for example, may improve bowel symptoms and reduce visceral hypersensitivity. This review summarizes the mechanisms of action of commonly used over-the-counter and prescription therapies for chronic idiopathic constipation and irritable bowel syndrome with constipation, outlining how these mechanisms contribute to the efficacy and safety of each treatment option. (Copyright © 2022 by The American College of Gastroenterology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|